Related Experiment Videos
Neonatal congenital microvillus atrophy
1Princess Margaret and King Edward Memorial Hospitals, Neonatal Clinical Care Unit, Subiaco, Western Australia.
Postgraduate Medical Journal
|February 19, 2004
Summary
Congenital microvillous atrophy (CMVA) causes severe neonatal diarrhea. Early diagnosis and management are crucial for improving the poor prognosis of this rare condition.
Area of Science:
- Pediatric Gastroenterology
- Neonatology
- Genetics
Background:
- Congenital microvillous atrophy (CMVA) is a rare, life-threatening cause of neonatal secretory diarrhea.
- It presents with either early-onset (within 72 hours) or late-onset (6-8 weeks) symptoms.
- Over 30 cases are reported globally, with a historically poor prognosis.
Purpose of the Study:
- To provide neonatologists and perinatologists with guidance for early diagnosis of CMVA.
- To outline current management strategies for neonatal secretory diarrhea due to CMVA.
- To assist healthcare providers in counseling parents of affected infants.
Main Methods:
- This review synthesizes existing literature on congenital microvillous atrophy.
- It focuses on clinical presentation, diagnostic approaches, and therapeutic outcomes.
- Information on survival rates and supportive care is discussed.
Main Results:
- Current treatments, including somatostatin and epidermal growth factor, offer limited benefit.
- Small bowel transplantation shows approximately 50% five-year survival.
- Early and accurate diagnosis remains a significant challenge.
Conclusions:
- Improved diagnostic criteria and timely intervention are essential for better outcomes in CMVA.
- Further research into effective therapies is urgently needed.
- Parental counseling requires comprehensive information on the condition's severity and prognosis.